Press Releases

Date Title  
Toggle Summary Natera Launches Initiative to Transform the Management of Cancer Patients in Organ Transplantation
Innovative technology platform for cell-free DNA testing in oncology and organ transplantation uniquely positions Natera to help improve outcomes for the most vulnerable transplant patients SAN CARLOS, Calif. , Sept. 14, 2020 /PRNewswire/ --  Natera, Inc.
Toggle Summary Natera's Signatera™ MRD Test Receives a Final Coverage Decision from Noridian in Colorectal Cancer
SAN CARLOS, Calif. , Sept. 11, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, the Medicare Administrative Contractor (MAC) for Northern California , has finalized a final local coverage article (LCA) to provide
Toggle Summary Natera Announces Pricing of Follow-On Offering
SAN CARLOS, Calif. , Sept. 10, 2020 /PRNewswire/ --  Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 4,166,666 shares of its common stock at a price to the public of $60.00 per share.
Toggle Summary Natera to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
SAN CARLOS, Calif. , Sept. 10, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Morgan Stanley 18th Annual Global Healthcare Conference taking place virtually on Monday, Sept.
Toggle Summary Natera Launches Proposed Follow-On Offering
SAN CARLOS, Calif. , Sept. 9, 2020 /PRNewswire/ -- Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $250,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day
Toggle Summary Natera Receives Final Medicare Coverage for its Signatera™ MRD Test in Stage II-III Colorectal Cancer
Creates patient access to first-of-its-kind, personalized ctDNA test to inform adjuvant treatment decisions and detect recurrence earlier than standard diagnostic tools SAN CARLOS, Calif. , Sept. 3, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA
Toggle Summary SMART Study Data for Aneuploidy and 22q Unblinded
Natera extends NIPT technology leadership with new Panorama® artificial intelligence platform SAN CARLOS, Calif. , Sept. 2, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and leader in cell-free DNA testing, today announced the unblinding of the SMART clinical trial data, and the
Toggle Summary Study Shows Clinical Utility of the Prospera™ Test in Nephrology Practice
Nephrologists using the Prospera donor-derived cell-free DNA (dd-cfDNA) test were more likely to correctly diagnose rejection and take the appropriate action SAN CARLOS, Calif. , Sept. 1, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today
Toggle Summary Natera Announces Collaboration with Massachusetts General Hospital for a Prospective Randomized Clinical Trial in Early Stage Breast Cancer
Study to use Signatera™ to test effectiveness of Ribociclib in combination with endocrine therapy versus standard endocrine therapy SAN CARLOS, Calif. , Aug. 27, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced a collaborative
Toggle Summary Natera's Signatera™ Test Receives CE Mark
Supports clinical use and implementation of global clinical trials SAN CARLOS, Calif. , Aug. 26, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it has received the CE mark for the Signatera test, a personalized,

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.